Impact of Nuedexta on Bulbar Physiology and Function in ALS
The purpose of this research is to determine if Nuedexta, an FDA approved and routinely prescribed medication, improves speech and swallowing functions in people with ALS.
If you agree to participate, you will be asked to attend 2 evaluations 30-days apart and undergo a swallowing x-ray study, cough testing, speech testing, and a tongue pressure exam.
- 18-90 years old
- Diagnosis of probable-definite ALS (El-Escorial Criterion); ALSFRS-R Bulbar subscale score <10
- Bamboo oral reading speaking rate <140 words per minute
- No allergies to barium sulfate
For additional study information, please contact Kelby Magennis:
- (352) 273-9725
Can be done from home
KeywordsALS, ALS - resources, Amyotrophic lateral sclerosis, Neurology
Principal InvestigatorEmily K. Plowman, PhD, CCC-SLP
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.